G-III Apparel Group Ltd. will replace Santarus Inc. in the S&P SmallCap 600 after the close of trading on Tuesday, December 31. S&P MidCap 400 constituent Salix Pharmaceuticals Ltd. is acquiring Santarus in a deal expected to be completed ...
Tags: G-III Apparel, Apparel
Pharming Group and Santarus have announced the submission of Ruconest (recombinant human C1 esterase inhibitor) biologics license application to the FDA. Investigational drug Ruconest 50 U/kg is being developed for the treatment of acute ...
Specialty biopharmaceutical company Santarus has announced the commercial launch of ulcerative colitis therapy, Uceris (budesonide) extended release tablets. Uceris that contains a locally acting glucocorticosteroid, budesonide, in a ...
Tags: Santarus, Uceris, ulcerative colitis therapy
Santarus has obtained FDA approval for ulcerative colitis therapy, Uceris (budesonide) extended release tablets. A 9mg dose tablet is approved for administration once a day in adult patients with ulcerative colitis for up to eight weeks. ...